MRK: Winrevair Breakthrough Drives Momentum as Stock Eyes $100
$Merck(MRK)$
95.05 USD：Winrevair Success Fuels Biotech Momentum, Eyes 100 Breakthrough》
Latest Close (ET): MRK closed at $95.05 (-1.43%), surging from yesterday's $96.43. The stock is now just 9.23% below its 52-week high of $105.07, showing robust recovery momentum from October lows.
Core Market Drivers: Merck's pulmonary drug Winrevair achieved primary endpoints in Phase 2 CADENCE study for pulmonary arterial hypertension, demonstrating statistically significant reduction in pulmonary vascular resistance; $9.2B Cidara Therapeutics acquisition for flu prevention drug CD388 strengthens pipeline diversification as Keytruda patent cliff approaches in 2028.
Technical Analysis:
Volume surged 79% above average (28.14M shares), indicating strong institutional participation;
RSI likely elevated near overbought territory following 3.84% single-day gain;
MACD momentum appears to be turning positive as stock breaks above key resistance levels around $93-95 range.
Key Price Levels:
Primary Support: $90.90-92 USD — Former resistance zone now providing technical floor
Strong Resistance: $97.50-100.00 USD — Psychological century mark and volume concentration area
Breakout Target: $105.00 USD — 52-week high retest upon sustained momentum
Valuation Perspective: Current P/E TTM of 12.76x remains reasonable compared to S&P 500's ~21x multiple, offering attractive relative value despite recent gains. Forward P/E of 10.36x suggests earnings growth acceleration supports current levels.
Analyst Targets: 26 institutions maintain average price target of $100.70, with range of $82-139. Recent upgrades include Mizuho ($92→$110) and UBS ($85→$107), reflecting growing confidence in pipeline execution.
Week Ahead Outlook: Expect consolidation within $93-100 range as market digests Winrevair data and Cidara integration timeline. Bullish continuation above $100 could target $105-108 resistance cluster; downside risk emerges below $92 support.
Risk Disclaimer:
This analysis is for informational purposes only and does not constitute investment advice. Stock performance remains subject to clinical trial outcomes, regulatory approvals, and broader market conditions. Please invest carefully.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD 5000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉
How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
